

## Christophe Richez



**Country:** France

**Contact e-mail:** [christophe.richez@mac.com](mailto:christophe.richez@mac.com)

**Year of birth:** 1976

**Mains diplomas:**

MD: 2000, Université de Bordeaux, France

Rheumatologist: 2005, Université de Bordeaux, France

PhD: 2009, Interferon-dependent and independent TLR signaling pathways in lupus pathogenesis, Université de Bordeaux, France

Specialisation in Clinical Immunology: 2009, Université de Bordeaux, France

**Current position and hospital/university:**

Professor of Rheumatology, Hospital Pellegrin, France

**Position within EULAR/international experience:**

EMEUNET member since 2010

Organizer of EULAR Immunology course

International experience: Research Scholar, Advisor: Dr. Ian Rifkin, Boston University, USA

**Role as EMEUNET working group member:**

Leader of the Global Affairs Subgroup

Member of the Education Subgroup: organization of the EULAR Immunology course

**Areas of Research/Interest:**

Clinical topic: Rheumatoid arthritis and Systemic lupus

Basic research: Immunology, Innate immunity, Interferon, T follicular helper cells

**Keywords:** Rheumatoid arthritis; lupus; interferon; dendritic cells; T follicular

helper cells

**Select Publications:**

- Khoryati L, Shipley E, Contin-Bordes C, Douchet I, Mitrovic S, Truchetet ME, Lazaro E, Duffau P, Couzi L, Jacquemin C, Vacher P, Schaefferbeke T, Blanco P, Richez C. IgE inhibits TLR-7 and -9 mediated expression of interferon-alpha by plasmacytoid dendritic cells in systemic lupus patients. *Arthritis Rheumatol* 2016;68(9):2221-31.
- Richez C, Truchetet ME, Schaefferbeke T, Bannwarth B. Atacicept as an investigated therapy for rheumatoid arthritis. *Expert Opin Investig Drugs*. 2014 Sep;23(9):1285-94.
- Richez C, Richards RJ, Duffau P, Weitzner Z, Andry CD, Rifkin IR, Aprahamian T. The effect of mycophenolate mofetil on disease development in the gld.apoE-/- mouse model of accelerated atherosclerosis and systemic lupus erythematosus. *PLoS One*. 2013;8(4):e61042.
- Richez C, Yasuda K, Bonegio RG, Watkins AA, Aprahamian T, Busto P, Richards RJ, Liu CL, Cheung R, Utz PJ, Marshak-Rothstein A, Rifkin IR. IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus. *J Immunol*. 2010 Jan 15;184(2):796-806.
- Yasuda K, Richez C, Uccellini MB, Richards RJ, Bonegio RG, Akira S, Monestier M, Corley RB, Viglianti GA, Marshak-Rothstein A, Rifkin IR. Requirement for DNA CpG content in TLR9-dependent dendritic cell activation induced by DNA-containing immune complexes. *J Immunol*. 2009 Sep 1;183(5):3109-17.
- Richez C, Schaefferbeke T, Dumoulin C, Dehais J, Moreau JF, Blanco P. Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab. *Arthritis Res Ther*. 2009 Jun 29;11(3):R100.
- Richez C, Yasuda K, Watkins AA, Akira S, Lafyatis R, van Seventer JM, Rifkin IR. TLR4 ligands induce IFN-alpha production by mouse conventional dendritic cells and human monocytes after IFN-beta priming. *J Immunol*. 2009 Jan 15;182(2):820-8.
- Yasuda K, Richez C, Maciaszek JW, Agrawal N, Akira S, Marshak-Rothstein A, Rifkin IR. Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. *J Immunol*. 2007 Jun 1;178(11):6876-85.

**Date of last update of the CV: September 2016**